Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1986 Aug;79(8):451–453. doi: 10.1177/014107688607900806

Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.

D J Evans, C W Burke
PMCID: PMC1290413  PMID: 3761287

Abstract

Forty-eight hirsute women were treated with spironolactone 100 mg twice daily for 3 to 12 months. Both facial and body hirsuties improved by 30-40%, and there was a threefold reduction in frequency of local treatments such as waxing or shaving. Plasma testosterone fell by 30%, though the improvement in hirsuties grading did not correlate with the fall in plasma testosterone. Six subjects discontinued treatment because of lack of effect, and 4 because of menstrual disturbance. Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome.

Full text

PDF
451

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramovici Y., Guillet F., Matte R., Chaieb L., Belanger R. La spironolactone dans l'hirsutisme idiopathique, évaluations clinique et biologique du traitement. Ann Endocrinol (Paris) 1983;44(6):393–396. [PubMed] [Google Scholar]
  2. Boisselle A., Dionne F. T., Tremblay R. R. Interaction of spironolactone with rat skin androgen receptor. Can J Biochem. 1979 Jul;57(7):1042–1046. doi: 10.1139/o79-131. [DOI] [PubMed] [Google Scholar]
  3. Boisselle A., Tremblay R. R. New therapeutic approach to the hirsute patient. Fertil Steril. 1979 Sep;32(3):276–279. doi: 10.1016/s0015-0282(16)44232-9. [DOI] [PubMed] [Google Scholar]
  4. Coney P. Polycystic ovarian disease: current concepts of pathophysiology and therapy. Fertil Steril. 1984 Nov;42(5):667–682. doi: 10.1016/s0015-0282(16)48189-6. [DOI] [PubMed] [Google Scholar]
  5. Cumming D. C., Yang J. C., Rebar R. W., Yen S. S. Treatment of hirsutism with spironolactone. JAMA. 1982 Mar 5;247(9):1295–1298. [PubMed] [Google Scholar]
  6. Dorrington-Ward P., McCartney A. C., Holland S., Scully J., Carter G., Alaghband-Zadeh J., Wise P. The effect of spironolactone on hirsutism and female androgen metabolism. Clin Endocrinol (Oxf) 1985 Aug;23(2):161–167. doi: 10.1111/j.1365-2265.1985.tb00211.x. [DOI] [PubMed] [Google Scholar]
  7. Eil C., Edelson S. K. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab. 1984 Jul;59(1):51–55. doi: 10.1210/jcem-59-1-51. [DOI] [PubMed] [Google Scholar]
  8. Greenblatt D. J., Koch-Weser J. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA. 1973 Jul 2;225(1):40–43. doi: 10.1001/jama.225.1.40. [DOI] [PubMed] [Google Scholar]
  9. Lobo R. A., Shoupe D., Serafini P., Brinton D., Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril. 1985 Feb;43(2):200–205. doi: 10.1016/s0015-0282(16)48373-1. [DOI] [PubMed] [Google Scholar]
  10. Menard R. H., Stripp B., Gillette J. R. Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism. Endocrinology. 1974 Jun;94(6):1628–1636. doi: 10.1210/endo-94-6-1628. [DOI] [PubMed] [Google Scholar]
  11. Messina M., Manieri C., Biffignandi P., Massucchetti C., Novi R. F., Molinatti G. M. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J Endocrinol Invest. 1983 Feb;6(1):23–27. doi: 10.1007/BF03350556. [DOI] [PubMed] [Google Scholar]
  12. Milewicz A., Silber D., Kirschner M. A. Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet Gynecol. 1983 Apr;61(4):429–432. [PubMed] [Google Scholar]
  13. Ober K. P., Hennessy J. F. Spironolactone therapy for hirsutism in a hyperandrogenic woman. Ann Intern Med. 1978 Nov;89(5 Pt 1):643–644. doi: 10.7326/0003-4819-89-5-643. [DOI] [PubMed] [Google Scholar]
  14. Shapiro G., Evron S. A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metab. 1980 Sep;51(3):429–432. doi: 10.1210/jcem-51-3-429. [DOI] [PubMed] [Google Scholar]
  15. Spandri P., Gangemi M., Nardelli G. B., Meneghetti G., Grandesso R., De Salvia D., Ambrosio G. B., Predebon O. Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy. Clin Exp Obstet Gynecol. 1984;11(1-2):49–54. [PubMed] [Google Scholar]
  16. Spironolactone and endocrine dysfunction. Ann Intern Med. 1976 Nov;85(5):630–636. doi: 10.7326/0003-4819-85-5-630. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES